Search company, investor...

Predict your next investment

Corporation
HEALTHCARE | Biotechnology
cnbg.com.cn

Investments

2

Partners & Customers

4

About China National Biotech Group

China National Biotech Group specializes in comprehensive research and product production of vaccines, blood products, animal health care, and medical beauty. The company was founded in 1989 and is based in Beijing, China.

Headquarters Location

15th Floor, Block 2, Fusheng Tower, Huixin East Street No.4 Chaoyang District

Beijing, Beijing,

China

010-84663377

Want to inform investors similar to China National Biotech Group about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest China National Biotech Group News

Study in China finds Covid-19 antibodies last at least 12 months

Jul 8, 2021

BEIJING (CHINA DAILY/ASIA NEWS NETWORK) - Antibodies against the novel coronavirus can last for at least 12 months in more than 70 per cent of recovered Covid-19 patients, a study published by Chinese researchers on Tuesday (July 6) shows. The finding adds to growing evidence that vaccination, which elicits an immune response in a way similar to how a live virus triggers human bodies to generate antibodies, can "effectively restrict the spread of Sars-CoV-2", the study said, referring to the novel coronavirus that causes Covid-19. The study, published online by Nature Communications, was conducted by China National Biotech Group, a Sinopharm subsidiary, and the National Research Centre for Translational Medicine at Shanghai Jiao Tong University. Researchers collected 1,782 convalescent plasma samples from 869 recovered Covid-19 patients in Wuhan, Hubei province, within 12 months of diagnosis, and tested them for the presence and amount of RBDIgG, a type of antibody that indicates the strength of immunity against the virus. Testing results showed that in nine months, levels of the antibody dropped to 64.3 per cent of the initial level when they contracted the virus, and then stabilised into the 12th month. "It shows that once immune responses against the novel coronavirus are induced in human bodies, antibody levels can be maintained for quite a long time," China National Biotech Group said in an article on its WeChat account on Wednesday. The study found that the antibody response was significantly stronger in male participants than in their female counterparts in the early stages of infection, but the difference dwindled over time and nearly disappeared in 12 months. Among participants aged 18 to 55, the more elderly ones developed higher antibody levels, it added. The company said the study is the longest-running research aimed at examining the persistence of antibody response in recovered Covid-19 patients. The finding was published as mass vaccination in China proceeds smoothly, with the country stepping up vaccine donations or sales overseas. As of Tuesday, about 1.3 billion doses of vaccines had been administered nationwide, the National Health Commission said on Wednesday. China National Biotech Group added that the study will help improve understanding of the immunological memory elicited by the virus, and provide guidance on future research into vaccine-induced immunity and future vaccination policies in China and abroad. More on this topic

China National Biotech Group Investments

2 Investments

China National Biotech Group has made 2 investments. Their latest investment was in Advanced Aesthetic Technologies as part of their Corporate Minority on September 9, 2019.

CBI Logo

China National Biotech Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/24/2019

Corporate Minority

Advanced Aesthetic Technologies

Yes

1

2/21/2019

Series A - II

Subscribe to see more

Subscribe to see more

10

Date

9/24/2019

2/21/2019

Round

Corporate Minority

Series A - II

Company

Advanced Aesthetic Technologies

Subscribe to see more

Amount

New?

Yes

Subscribe to see more

Co-Investors

Sources

1

10

China National Biotech Group Partners & Customers

4 Partners and customers

China National Biotech Group has 4 strategic partners and customers. China National Biotech Group recently partnered with ImmBio on April 4, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

4/17/2019

Licensor

United Kingdom

ImmBio enters licensing and co-development deal with China National Biotec Group for PnuBioVax™

China National Biotec Group and ImmunoBiology Ltd enter licensing agreement to co-develop next generation vaccine against pneumococcal disease in Greater China .

1

6/22/2009

Partner

United States

Subscribe to see more

Subscribe to see more

10

Partner

United States

Subscribe to see more

Subscribe to see more

10

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

4/17/2019

6/22/2009

Type

Licensor

Partner

Partner

Partner

Business Partner

Country

United Kingdom

United States

United States

United States

News Snippet

ImmBio enters licensing and co-development deal with China National Biotec Group for PnuBioVax™

China National Biotec Group and ImmunoBiology Ltd enter licensing agreement to co-develop next generation vaccine against pneumococcal disease in Greater China .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.